New US HQ Opens As Creo Focuses On Global Growth
Creo Medical Group has opened a new US headquarters in Connecticut which the Welsh medical device company said illustrated its “commitment to growth” and its focus on the key market in the US.
The space – located at Summit, Danbury, Connecticut – is designed to support Creo’s global growth and focus in the US market and features a learning centre and a fully equipped laboratory for clinical development and training purposes.
This will support Creo’s education-led commercialisation strategy and enable healthcare providers to participate in immersive, didactic ex-vivo training sessions. US customer service, finance, product logistics, distribution and other day-to-day functions will also be based in the Danbury office.
Located, north-east of New York city, the office’s proximity to international airports was said to provide convenient access for visiting clinicians and members of staff.
Over the past 18 months, Creo has established a direct commercial team in the US, led by experienced and successful leaders in market development.
Creo’s CROMA Energy Generator platform is in place at multiple academic institutions across the US, with key opinion leaders trained through Creo’s Clinical Education Programme.
The company intends to increase the number of US installations and training centres to support the scaling of its presence in the country.
Craig Gulliford, chief executive at Creo, said: “We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States market. These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market.”
David Woods, chief commercial officer of Creo, added: “Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device company.
“The opening of this clinical training and commercial support facility in the United States represents the next phase in our planned and sustained development and further illustrates our growth and focus in the United States region, which gives even greater access to another important market.”